7-oxo-7H-benzo[e]perimidine-4-carboxylic acid | 65359-16-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 7-oxo-7H-benzo[e]perimidine-4-carboxylic acid
• 英文别名: 7-oxo-7H-benzo[e]pyrimidine-4-carboxylic acid；7-oxobenzo[e]perimidine-4-carboxylic acid；BAS00368055；7-oxo-7H-benzo[e]perimidine-4-carboxylic acid；7-Oxo-7H-benzo[e]perimidin-4-carbonsaeure
• CAS: 65359-16-2
• 化学式: C₁₆H₈N₂O₃
• 分子量: 276.251
• InChiKey: NARZOZMHJMTCGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-oxo-7H-benzo[e]perimidine-4-carboxylic acid 以 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 N-(2-aminoethyl)-20-oxo-3,6,10,12-tetrazapentacyclo[11.7.1.02,7.09,21.014,19]henicosa-1(21),2(7),8,10,12,14,16,18-octaene-8-carboxamide
  参考文献：
  名称：

  Synthesis and biological activity of oxo-7H-benzo[e]perimidine-4-carboxylic acid derivatives as potent, nonpeptide corticotropin releasing factor (CRF) receptor antagonists

  摘要：

  A novel series of derivatives of oxo-7H-benzo[e]perimidine-4-carboxylic acid (I) potently displaced radioligand binding of I-125-CRF to both CRF1 and CRF2 receptors. The members of this series antagonized CRF-stimulated cAMP formation and CRF-stimulated corticotropin release from rat pituitary in vivo. These are the first nonpeptide antagonists to show activity at both CRF1 and CRF2 receptors. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00075-x
• 作为产物：
  描述：

  聚合甲醛 、 1-氨基蒽醌-2-羧酸 在 氨 、 水 作用下， 生成 7-oxo-7H-benzo[e]perimidine-4-carboxylic acid
  参考文献：
  名称：

  DE711775

  摘要：

  公开号：

文献信息

• FACILE PREPARATION OF 4-SUBSTITUTED QUINAZOLINES AND RELATED HETEROCYCLES
  申请人：Wang Zerong Daniel

  公开号：US20120283436A1

  公开（公告）日：2012-11-08

  A straightforward single step method for the preparation and/or production of substituted quinazolines is disclosed, wherein said quinazolines preferably contain one substituent at position 4, and may contain other functional groups at various positions, such as 5, 6, 7, and/or 8 of quinazolines. In addition, the extension of this new method leads to the formation of different type of heterocyclic aromatic compounds, that include but are not limited to perimidines, anthrapyrimidin-7-ones (also known as anthrapyrimidinones), anthra[1,9:5,10]dipyrimidines (also known as quinazoline[5,4-ef]perimidines) and benzo[e]-pyrimido[4,5,6-gh]pyrimidines.

  本发明揭示了一种制备和/或生产取代喹唑啉的简单单步方法，其中所述喹唑啉优选在位置4处含有一个取代基，并且可能在喹唑啉的各种位置，例如5、6、7和/或8处含有其他官能团。此外，这种新方法的扩展还导致不同类型的杂环芳香化合物的形成，包括但不限于咪唑啉、蒽吡咯啉-7-酮（也称为蒽吡咯啉酮）、蒽[1,9:5,10]二咪唑啉（也称为喹唑啉[5,4-ef]咪唑啉）和苯并[e]-嘧啶[4,5,6-gh]嘧啶。
• Medicament for liver regeneration and for treatment of liver failure
  申请人：HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GmbH

  公开号：US10188682B2

  公开（公告）日：2019-01-29

  The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.

  本发明涉及一种抑制 MKK4 活性的化合物作为治疗肝功能受损患者的药物的用途，涉及一种化合物作为治疗肝衰竭（包括急性/严重或慢性肝衰竭）和/或增加患者肝组织再生的药物的用途。
• Antonini; Polucci; Cola, Il Farmaco, 1992, vol. 47, # 11, p. 1385 - 1393
  作者：Antonini、Polucci、Cola、Palmieri、Martelli

  DOI：——

  日期：——
• DE711775
  申请人：——

  公开号：——

  公开（公告）日：——
• METHOD OF TRANSCRIPTIONALLY MODULATING GENE EXPRESSION AND OF DISCOVERING CHEMICALS CAPABLE OF FUNCTIONING AS GENE EXPRESSION MODULATORS
  申请人：OSI Pharmaceuticals, Inc.

  公开号：EP0483249B1

  公开（公告）日：2003-04-23